VJHemOnc Podcast
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
Mentioned books
Feb 2, 2023 • 11min
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
Experts Michael Dickinson and Tycel Phillips discuss updates in non-Hodgkin lymphoma at ASH 2022, including the TRIANGLE trial, the changing role of transplantation, and novel immunotherapies in the field.
Jan 26, 2023 • 14min
MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
Experts Aaron Gerds and Lucia Masarova discuss key updates in myeloproliferative neoplasms (MPNs) presented at ASH 2022, including the MOMENTUM trial, combination approaches, and novel agents like calreticulin-targeting antibodies. They also explore advancements in fibrosis treatment, the role of immunotherapies in eliminating malignant clones, and challenges in MPN treatment for accelerated and blast phase diseases.
Jan 20, 2023 • 9min
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
Experts Kate Cwynarski and Swaminathan Iyer discuss T-cell lymphoma updates from ASH 2022, including the importance of real-world data, addressing CNS relapse, and novel treatment approaches being explored. They also highlight the potential of targeted trials and the significance of global collaborations in improving patient outcomes.
Jan 17, 2023 • 7min
The importance of CD47 in MDS and other targets of interest
Naval Daver, MD, an expert in hematological malignancies, discusses the importance of CD47 in MDS and other targets of interest. The podcast covers the mechanism of action of anti-CD47 antibodies, current agents under investigation, and future considerations for clinical trials in MDS, including other targets and triplet combinations.
Jan 9, 2023 • 7min
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
Leading CLL experts, Matthew Davids and Lindsey Roeker, discuss recent updates in CLL treatment, including doublet and triplet therapies, clinical trial updates, and the impact of novel BTK inhibitors. They also highlight the improvements in safety profile and progression-free survival benefit with longer follow-up of covalent BTK inhibitors in CLL treatment.
Jan 3, 2023 • 15min
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
Yi Lin from Mayo Clinic and Krina Patel from MD Anderson Cancer Center discuss key updates in multiple myeloma presented at ASH 2022. They talk about real-world experiences with access to CAR-T therapy, optimizing sequencing of therapies, ongoing clinical trials in high-risk disease, and more.
Dec 21, 2022 • 14min
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
Doctors David Sallman and Andrew Brunner discuss updates in myelodysplastic syndromes at ASH 2022. Topics include treatment options for lower-risk and higher-risk disease, trial updates, novel classification systems, and therapies after failure to hypomethylating agents.
Dec 16, 2022 • 12min
iwNHL Session V: novel therapies in NHL – the role of ADCs
Laurie Sehn and Carmelo Carlo Stella discuss novel therapies in NHL, focusing on antibody-drug conjugates (ADCs). They talk about the updates on ADCs like brentuximab vedotin, loncastuximab tesirine, and more, and their place in the treatment landscape. Topics include the promising results of Bratuxima of Badoten, comparing a novel therapy with standard treatment, exploring a promising ADC for lymphomas, and the efficacy of pulatuzumab in diffuse large bicell lymphoma treatment.
Dec 6, 2022 • 13min
iwAL 2022 Session V: mechanisms of resistance to targeted therapies in AML
Naval Daver and Paresh Vyas discuss mechanisms of resistance to targeted therapies in AML, including the impact of small clones and non-cell intrinsic effects. They explore the modulation of leukemia by therapies and the potential of using companion diagnostics and immunotherapies to predict long-term responders. The podcast also highlights the importance of testing for flip three mutation in AML patients and the role of epigenetic targets in therapy resistance.
Dec 2, 2022 • 10min
The importance of genomic testing in CLL and its role in clinical decision-making
Experts discuss the importance of genomic testing in CLL including defining high-risk disease, the significance of TP53 mutations, using genomic testing to identify treatment strategies, challenges in treating double refractory patients, and the potential of novel targeted agents to improve outcomes.
